{
    "clinical_study": {
        "@rank": "104363", 
        "arm_group": [
            {
                "arm_group_label": "BK1301", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "DT toxoid", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This study is designed to assess the immunogenicity and safety of DTaP vaccine (BK1301) as a\n      booster dose in adolescents.\n\n      The purposes of this study are as follows:\n\n        -  To confirm the non-inferiority of BK1301 to Adsorbed Diphtheria-Tetanus Combined Toxoid\n           (DT toxoid) with respect to booster responses for anti-diphtheria toxoid (anti-D) and\n           anti-tetanus toxoid (anti-T) antibodies\n\n        -  To confirm that booster responses for anti-pertussis toxoid (anti-PT) and\n           anti-Filamentous Hemagglutinin (anti-FHA) antibodies are more than 80% of participants\n           received BK1301"
        }, 
        "brief_title": "Study of BK1301 (DTaP Vaccine) as a Booster in Adolescents", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Diphtheria", 
            "Tetanus", 
            "Pertussis"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diphtheria", 
                "Whooping Cough", 
                "Tetanus", 
                "Tetany"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 11 or 12 years on the day of injection\n\n          -  Received 3 or 4 doses of DTaP vaccine\n\n        Exclusion Criteria:\n\n          -  History of pertussis, diphtheria, tetanus\n\n          -  History of anaphylaxis to vaccine components\n\n          -  Serious conditions or diseases of the heart, vein, blood, respiratory, hepar, kidney,\n             digestive system, psychiatric or nervous system\n\n          -  Transfused or received gamma globulin within 3 months, or received high-dose gamma\n             globulin within 6 months before the day of injection"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "12 Years", 
            "minimum_age": "11 Years"
        }, 
        "enrollment": {
            "#text": "430", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 13, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02118961", 
            "org_study_id": "BKD1A"
        }, 
        "intervention": [
            {
                "arm_group_label": "BK1301", 
                "description": "0.5 mL, subcutaneous injection", 
                "intervention_name": "Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP vaccine, BK1301)", 
                "intervention_type": "Biological", 
                "other_name": "TRIBIK\u00ae"
            }, 
            {
                "arm_group_label": "DT toxoid", 
                "description": "0.1 mL, subcutaneous injection", 
                "intervention_name": "Adsorbed Diphtheria-Tetanus Combined Toxoid (DT toxoid)", 
                "intervention_type": "Biological", 
                "other_name": "DTBIK\u00ae"
            }
        ], 
        "is_fda_regulated": "No", 
        "keyword": [
            "Diphtheria", 
            "Tetanus", 
            "Pertussis", 
            "DTaP vaccine", 
            "Adolescents"
        ], 
        "lastchanged_date": "April 18, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka-shi", 
                        "country": "Japan", 
                        "state": "Fukuoka"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Itoshima-shi", 
                        "country": "Japan", 
                        "state": "Fukuoka"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kasuga-shi", 
                        "country": "Japan", 
                        "state": "Fukuoka"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hiroshima-shi", 
                        "country": "Japan", 
                        "state": "Hiroshima"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumagaya-shi", 
                        "country": "Japan", 
                        "state": "Saitama"
                    }, 
                    "name": "Inverstigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shizuoka-shi", 
                        "country": "Japan", 
                        "state": "Shizuoka"
                    }, 
                    "name": "Investigational site"
                }, 
                "status": "Not yet recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Shinjuku-ku", 
                        "country": "Japan", 
                        "state": "Tokyo"
                    }, 
                    "name": "Inverstigational site"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Japan"
        }, 
        "number_of_arms": "2", 
        "official_title": "Confirmatory Study to Evaluate the Immunogenicity of Diphtheria and Tetanus Toxoids and Acellular Pertussis Vaccine Adsorbed (DTaP Vaccine, BK1301) as a Booster in Adolescents", 
        "overall_contact": {
            "email": "crdcontact@mail.biken.or.jp", 
            "last_name": "Clinical Development R&D"
        }, 
        "overall_contact_backup": {
            "email": "cti-inq-ml@ml.mt-pharma.co.jp", 
            "last_name": "Clinical Trials Information Desk"
        }, 
        "overall_official": {
            "affiliation": "Osaka University", 
            "last_name": "Shintaro Okada, M.D., Ph.D.", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of participants with booster responses for anti-D and anti-T antibodies", 
                "safety_issue": "No", 
                "time_frame": "pre-vaccination and 28-42 days after vaccination"
            }, 
            {
                "measure": "Percentage of participants with booster responses for anti-PT and anti-FHA  antibodies", 
                "safety_issue": "No", 
                "time_frame": "pre-vaccination and 28-42 days after vaccination"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02118961"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Percentage of participants with anti-D and anti-T antibody titers above protocol defined cut-off values", 
                "safety_issue": "No", 
                "time_frame": "28-42 days after vaccination"
            }, 
            {
                "measure": "Percentage of participants with anti-PT and anti-FHA antibody titers above protocol defined cut-off values", 
                "safety_issue": "No", 
                "time_frame": "28-42 days after vaccination"
            }, 
            {
                "measure": "Geometric mean titers (GMTs) of anti-D and anti-T antibodies", 
                "safety_issue": "No", 
                "time_frame": "28-42 days after vaccination"
            }, 
            {
                "measure": "GMTs of anti-PT and anti-FHA antibodies", 
                "safety_issue": "No", 
                "time_frame": "28-42 days after vaccination"
            }, 
            {
                "measure": "Increase in GMTs of anti-D and anti-T antibodies", 
                "safety_issue": "No", 
                "time_frame": "pre-vaccination and 28-42 days after vaccination"
            }, 
            {
                "measure": "Increase in GMTs of anti-PT and anti-FHA antibodies", 
                "safety_issue": "No", 
                "time_frame": "pre-vaccination and 28-42 days after vaccination"
            }, 
            {
                "measure": "Percentage of participants with Adverse Events", 
                "safety_issue": "Yes", 
                "time_frame": "28-42 days following vaccination"
            }
        ], 
        "source": "Mitsubishi Tanabe Pharma Corporation", 
        "sponsors": {
            "collaborator": {
                "agency": "The Research Foundation for Microbial Diseases of Osaka University", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "Mitsubishi Tanabe Pharma Corporation", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}